Cadrenal Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Cadrenal Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Cash Flow-to-Debt Ratio of -2.82x as of March 2026, meaning its operating cash flow of $-3.00 Million could theoretically repay -3% of its total liabilities ($1.06 Million) in one year. See Cadrenal Therapeutics, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
Cash flow-to-debt ratio of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025. Historical debt coverage capacity for Cadrenal Therapeutics, Inc. Common Stock across 4 annual periods. Check Cadrenal Therapeutics, Inc. Common Stock cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cadrenal Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2025)
Cadrenal Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Cadrenal Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see CVKD operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -7.94x | $-12.60 Million | $1.59 Million | ▼ -189.5% |
| 2024 | -2.74x | $-7.36 Million | $2.68 Million | ▲ +35.8% |
| 2023 | -4.27x | $-3.53 Million | $826.88K | ▼ -2143.0% |
| 2022 | -0.19x | $-1.20 Million | $6.33 Million | — |